Jean-François LEOCATA, INNOMedX‘s Founder and CEO, has wide experience in the medical industry. He trained as a radiographer and for the last 30 years he has held a variety of significant positions within leading companies in this field. He has headed sales, marketing and strategy teams and has contributed to the development and success of both large organisations and start-ups in France, Europe, Middle-East, Africa (EMEA) and Internationally.

For the last 25 years he has specialised in percutaneous and endovascular interventional techniques in Neuroradiology, Neurosurgery, Radiology and Cardiology. He is well known for his innovative and meticulous development of products and techniques in Interventional Neuroradiology.

For the last 15 years he has shared his expertise with a company which has become a leader in the endovascular treatment of stroke. With the involvement of European and International Neuroradiologists, he helped initiate Thrombectomy by Aspiration Techniques. As the technique of thromboaspiration has proved to be clinically so effective, it is now being used peripherally by Interventional Radiologists and Vascular Surgeons

Sarah-Lou SERERO, gained her Doctorate of Pharmacy from the University of Paris Descartes and her Masters in Regulatory Affairs and Market Access from Bordeaux University.

She has quickly developed a name for herself by her successful work and considerable expertise. Her speciality is the early reimbursement systems (Innovation Package and Transitional Reimbursement).

She worked for many years with an expert consulting company where she held various positions of responsability. In this post she aquired wide-ranging experience in all paths leading to market access and reimbursement for innovative health technologies.

Sarah-Lou assists start-ups and MedTech companies in their efforts to access the market at the European (EMEA) and international level. Her analysis and implementation of specific strategies, followed by the setting up of the operational phase – advising manufacturers in their discussions with health authorities – result in early and sustainable reimbursement.

Since joining INNOMedX, Sarah-Lou participates in the management of all the company’s missions.
As Manager of Market Access and Reimbursement in France, Europe, (EMEA) and international, she develops the customer portfolio.

Salma BAGHAGHA gained her Masters from the ICN Business School in Nancy, France, in Management specialising in Marketing and Communication, where she developed her expertise in the fundamental principles of management.

In order to extend her skills in strategic and operational management at an international level, Salma studied in Canada and was awarded an MBA from the Laval University of Quebec.

With her exemplary academic and professional background and her 7 years of experience in business administration, she has headed operations in business communication specialising in Market Access and reimbursement of innovative medical technologies. She has developed a broad holistic expertise in MedTech innovations.

Salma joins INNOMedX as Head of Operations and Communications, France, Europe (EMEA) and international. She supervises the Communications, Sales Administration and Customer Relations departments and co-ordinates commercial development and subcontracting management.

Committed to maintaining operational excellence at INNOMedX, Salma provides customers & partners with an individualised, clear and sustainable experience.

With over 30 years of experience in luxury interior design, she has built a distinguished career specializing in the restoration and decoration of châteaux, historic estates, and high-end residences across France, England, and the United States. She is renowned for her artistic sensibility, mastery of fine materials, and ability to elevate exceptional spaces while preserving their heritage and character.

Throughout her journey, Marlène developed strong expertise in managing complex, high-budget projects, which naturally led her to take on financial leadership responsibilities. Now serving as Chief Financial Officer, she brings a rare blend of aesthetic vision and strategic discipline, ensuring cost optimization while upholding the highest standards of quality. Her dual background makes her a unique asset, seamlessly aligning art, heritage, and financial performance.

Dr. Jérôme BERGE: “After completing a radiology residency in Bordeaux, I began my academic hospital fellowship (AHU – Assistanat Hospitalier Universitaire) in radiology in 1991, combined with a position in neurophysiology. My mission: to develop the interventional neuroradiology (INR) activity at the Bordeaux University Hospital (CHU de Bordeaux).

The introduction of endovascular treatments for intracranial aneurysms as early as 1991, followed in 2015 by the advent of Mechanical Thrombectomy (MT) as a first-line treatment for severe ischemic strokes, significantly contributed to the growth of our team, now composed of six INR specialists. We currently perform over 1,000 embolization procedures annually in Bordeaux, ranking among the top three INR centers in France for several years. In recent years, we have recorded more than 350 embolized aneurysms, 400 thrombectomies, 100 arteriovenous malformations (AVMs) and dural arteriovenous fistulas, as well as 200 additional procedures including angioplasties, vasospasm treatments, and subdural hematoma.

The rise of Thrombectomy has enabled me—first at the regional level and then nationally, following my election to the executive board of the French Society of Neuroradiology (SFNR)—to optimize patient pathways toward Thrombectomy-capable centers. I was the first in the Nouvelle-Aquitaine region to coordinate the opening of new thrombectomy centers within General Hospitals (CHG), by training Interventional Radiologists in Bayonne and Pau. Our region has since served as a national model for the implementation of approximately twenty new thrombectomy centers (“Type A Centers”), either already operational or in the process of opening. The objective is consistent across all: to improve patient access to MT within optimal timeframes, thereby enhancing neurological outcomes.

Andrew ORTEGA-VERDAGUER brings over 15 years of international executive experience in marketing, commercial excellence, and business strategy, leading large teams across top pharmaceutical and medical device companies such as Novartis, Terumo, and Penumbra Inc.

Throughout his career, he has successfully launched more than 20 products into international markets, driving adoption and growth across multiple regions.

Graduated of the Stanford GSB IGNITE Program and has pursued further studies at several other prestigious international business schools. Today, Andrew combines his deep industry expertise with a passion for innovation to advance transformative healthcare solutions.

With over 30 years of experience in the MedTech industry, Olivier RAPPA is a seasoned expert in Business Development. He possesses a robust R&D network, encompassing incubators and innovation ecosystems and maintains global reach through a network of 150 distributors across Surgery, Gynaecology, Gastroenterology, and Urology.

As a Partner and Strategic Board Member, he brings an entrepreneurial spirit and strong commercial acumen, with proven expertise spanning global B2B and B2C markets, including pharmaceuticals, healthcare, medical devices, and professional and corporate sectors.

A collaborative leader, he engages effectively with stakeholders at Board and C-suite levels, driving operational excellence, business transformation and sustainable profitability.

Olivier has extensive international experience in the medical device and capital equipment sectors, having successfully operated across Europe, Asia-Pacific, the Middle East, and both North and South America.

Pharmacist and health economist, Leila holds a Master’s degree (Master 2) from the University of Paris-Est Créteil (UPEC) and has several years of experience as a consultant specializing in the submission of dossiers and strategic analyses related to Health Technology Assessment (HTA).

With her training in clinical trial methodology at the University of Paris Cité, Leila has developed strong expertise in the critical analysis of clinical data—an essential asset for assessing the medical and economic value of health technologies within reimbursement dossiers.

Her skill set enables her to excel in drafting study protocols, conducting literature reviews in line with regulatory expectations, and performing critical appraisals of scientific publications.

Leila joined INNOMedX’s Market Access department, where she brings her experience and precision to the successful management of projects.

Following her training in Artificial Intelligence and Pharmaceutical Sciences and her pharmacy studies at the University of Paris-Saclay (Orsay), Ngoc-Yên specialized in Market Access through a Master’s degree (Master 2) in Health Economics and Market Access before joining the INNOMedX’s team.

Ngoc-Yên has a strategic vision that enables her to identify the optimal reimbursement pathway for a health technology and possesses strong expertise in drafting LPPR dossiers, particularly the medico-technical sections.

Her effective approach to planning and managing projects is highly valued by our clients.

Hamid is currently completing his Doctor of Pharmacy degree – Industry track – at the University of Montpellier, alongside a Master’s degree (Master 2) in Market Access and Health Technology Assessment at the University of Lyon 1.

This dual academic background enables him to develop strong expertise in the medico-economic evaluation of healthcare products, pharmacoeconomics, reimbursement and pricing strategies, as well as cost-effectiveness and cost-utility analyses.

Hamid applies his skills in Market Access and medical device evaluation within the Market Access department of INNOMedX’s.